660 related articles for article (PubMed ID: 17656655)
1. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
3. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
4. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
[TBL] [Abstract][Full Text] [Related]
5. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
Kögel B; De Vry J; Tzschentke TM; Christoph T
Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
[TBL] [Abstract][Full Text] [Related]
6. Tapentadol hydrochloride: a centrally acting oral analgesic.
Wade WE; Spruill WJ
Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
[TBL] [Abstract][Full Text] [Related]
7. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
Christoph T; De Vry J; Tzschentke TM
Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterization of tapentadol metabolites.
Terlinden R; Kogel BY; Englberger W; Tzschentke TM
Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344
[TBL] [Abstract][Full Text] [Related]
9. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
10. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
[TBL] [Abstract][Full Text] [Related]
11. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit.
Cowan A; Raffa RB; Tallarida CS; Tallarida RJ; Christoph T; Schröder W; Tzschentke TM
Eur J Pain; 2014 Sep; 18(8):1148-56. PubMed ID: 24574066
[TBL] [Abstract][Full Text] [Related]
12. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis.
Tzschentke TM; Folgering JH; Flik G; De Vry J
Neurosci Lett; 2012 Jan; 507(2):151-5. PubMed ID: 22197547
[TBL] [Abstract][Full Text] [Related]
13. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
Hartrick CT
Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
[TBL] [Abstract][Full Text] [Related]
14. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
[TBL] [Abstract][Full Text] [Related]
16. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
Meske DS; Xie JY; Oyarzo J; Badghisi H; Ossipov MH; Porreca F
Neurosci Lett; 2014 Mar; 562():91-6. PubMed ID: 23969300
[TBL] [Abstract][Full Text] [Related]
17. Tapentadol for pain: a treatment evaluation.
Hartrick CT; Rodríguez Hernandez JR
Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
[TBL] [Abstract][Full Text] [Related]
18. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
Candiotti KA; Gitlin MC
Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
[TBL] [Abstract][Full Text] [Related]
19. Effects of tapentadol on mechanical hypersensitivity in rats with ligatures of the infraorbital nerve versus the sciatic nerve.
Michot B; Bourgoin S; Kayser V; Hamon M
Eur J Pain; 2013 Jul; 17(6):867-80. PubMed ID: 23229959
[TBL] [Abstract][Full Text] [Related]
20. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain.
Christoph T; Kögel B; Schiene K; Méen M; De Vry J; Friderichs E
Eur J Pharmacol; 2005 Jan; 507(1-3):87-98. PubMed ID: 15659298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
